![]() ![]() For more information on how Novamind is enhancing mental wellness and guiding people through their entire healing journey, visit novamind.ca. Both Cedar Psychiatry and Cedar Clinical Research are wholly owned subsidiaries of Novamind. Novamind provides ketamine-assisted psychotherapy and other novel treatments through its network of Cedar Psychiatry clinics and operates Cedar Clinical Research, a contract research organization specialized in clinical trials and evidence-based research for psychedelic medicine. Novamind is a leading mental health company enabling safe access to psychedelic medicine through a network of clinics, retreats, and clinical research sites. The OTCQB quality standards provide a strong baseline of transparency, as well as the technology and regulation to improve the information and trading experience for investors. To be eligible, companies must be current in their reporting and undergo an annual verification and management certification process, including meeting a minimum bid price and other financial conditions. and international companies that may not yet qualify for OTCQX. The OTCQB offers investors transparent trading in entrepreneurial and development stage U.S. "Having the Company's common shares posted for trading on the OTCQB and providing a more efficient way of trading our shares will be an important milestone in our strategy of building awareness and enhancing accessibility amongst United States investors looking for exposure to the growth potential of Novamind's mental health and psychedelic medicine business," said Yaron Conforti, CEO and Director of Novamind. ![]() The Company currently trades and will continue to trade on the Canadian Securities Exchange ("CSE") under its existing symbol "NM" and on the Frankfurt Stock Exchange ("FSE") under its existing symbol "HN2". and the satisfaction of applicable eligibility requirements. The posting of the Company's common shares for trading on the OTCQB remains subject to the approval of the OTC Markets Group, Inc. The Company has also applied for Depository Trust Company (DTC) eligibility which would greatly simplify the process of trading the Company's common shares. trading platform operated by the OTC Markets Group, Inc. ![]() (CSE:NM)(OTC PINK:NVMDF)(FSE:HN2) ("Novamind" or the "Company"), a leading mental health company specialized in psychedelic medicine, is pleased to announce that it has submitted its application to have its common shares posted for trading on the OTCQB® Venture Market (the "OTCQB"), a U.S. TORONTO, ON / ACCESSWIRE / J/ Novamind Inc. We are excited to join Numinus, a true leader in mental health innovation.Aims to increase visibility and facilitate investment for United States investors The combined entity is supported with over CA$50 million in pro-forma capital and positioned with distinct capabilities to serve a growing and diverse group of stakeholders. and Numinus' leadership in psychedelic-assisted psychotherapy in Canada creates a best-in-class company. The combination of Novamind's network of mental health clinics and research sites in the U.S. Yaron Conforti, CEO and co-founder, Novamind, stated, "This transaction offers significant value for Novamind's shareholders and provides compelling new opportunities for our employees, patients and research partners. We look forward to welcoming the Novamind team to the Numinus family." Our combined capabilities will deliver exceptional value for our clients, employees, and shareholders. Nyquvest continued: "We expect this acquisition will significantly bolster our financial performance, growing Numinus' annual revenue to more than five times our current levels, and driving meaningful margin improvement through identified operating efficiencies. market presence, complementary client programming and respected clinical research capabilities allow us to accelerate our strategic growth plans and broaden access to healing and wellness." "We prioritize working with the best partners in this industry and Novamind's U.S. platform through eight established, reputable, efficiently operating and revenue-producing clinics," stated Payton Nyquvest, founder and CEO, Numinus. The Novamind acquisition presents a transformational opportunity for Numinus to launch a strong U.S. "Since Numinus began, we have always strived to be the most trusted, evidence-based leader in psychedelic-assisted therapy and medicine. ![]()
0 Comments
Leave a Reply. |